TachoSil sealant matrix

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 24/01/20

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 24/1/2020

Click on this link to Download PDF directly

Takeda Products Ireland Ltd

Takeda Products Ireland Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Actos tablets Active Ingredients pioglitazone hydrochloride
Medicine Name Adcetris 50 mg powder for concentrate for solution for infusion Active Ingredients Brentuximab vedotin
Medicine Name Alofisel 5 million cells/mL suspension for injection Active Ingredients Human Allogeneic Mesenchymal Adult Stem Cells
Medicine Name Alunbrig Active Ingredients Brigatinib
Medicine Name Blopress Plus Tablets Active Ingredients Candesartan Cilexetil, Hydrochlorothiazide
Medicine Name Blopress tablets Active Ingredients Candesartan Cilexetil
Medicine Name Calcichew 500mg Chewable Tablets Active Ingredients Calcium Carbonate
Medicine Name Calcichew-D3 Forte Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Calcichew-D3 Forte Double Strength 1000 mg/800 IU chewable tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Competact 15 mg/850 mg film-coated Tablets Active Ingredients Metformin Hydrochloride, pioglitazone hydrochloride
Medicine Name Condyline Cutaneous Solution 5 mg/ml Active Ingredients Podophyllotoxin
Medicine Name Edarbi Tablets Active Ingredients Azilsartan medoxomil potassium
Medicine Name Entyvio 300 mg powder for concentrate for solution for infusion Active Ingredients Vedolizumab
Medicine Name Instanyl 50, 100 and 200 mcg nasal spray, solution in single-dose container Active Ingredients fentanyl citrate
Medicine Name Matrifen Transdermal patch Active Ingredients Fentanyl
Medicine Name Mepact 4mg powder for suspension for infusion Active Ingredients Mifamurtide
Medicine Name Midon 2.5 mg Tablets Active Ingredients Midodrine Hydrochloride
Medicine Name Midon 5 mg Tablets Active Ingredients Midodrine Hydrochloride
Medicine Name NINLARO 2.3 mg, 3 mg, 4 mg hard capsules Active Ingredients Ixazomib Citrate
Medicine Name Prostap 3 DCS Active Ingredients Leuprorelin Acetate
Medicine Name Prostap 6 DCS Active Ingredients Leuprorelin Acetate
Medicine Name Prostap SR DCS Active Ingredients Leuprorelin Acetate
Medicine Name Protium 20mg Active Ingredients Pantoprazole sodium sesquihydrate
Medicine Name Protium 40mg Active Ingredients Pantoprazole sodium sesquihydrate
Medicine Name Protium 40mg iv Active Ingredients Pantoprazole sodium sesquihydrate
1 - 0 of 26 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24 January 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 24 January 2020 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Section

Changes

4.4. Special warnings and precautions for use

 

Deletion / addition of text:

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

It is strongly recommended that every time TachoSil is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

4.8

Updated to:

HPRA Pharmacovigilance  Website: www.hpra.ie  

10. date of the revision of the text

6th December 2019

Updated on 22 August 2019 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to restricted prescription (C)

Updated on 8 June 2018 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Minor typographical errors have been corrected and the Date of revision of the text updated to 25th May 2018 

Updated on 8 June 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision

Updated on 11 April 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to restricted prescription (C)

Updated on 11 April 2016 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Change to section

Details of change

4.1 Therapeutic Indications

Text in blue removed and text in red added:

 

TachoSil is indicated in adults for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient, and for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1).

 

4.4 Special warnings and precautions for use

Text in blue removed and text in red added:

 

Do not use intravascularly. Life threatening thromboembolic complications may occur if the preparation is applied intravascularly.

 

Specific data have not been obtained on the use of this product in neurosurgery or in gastrointestinal anastomoses surgery.

 

It is not known whether recent radiation therapy affects the efficacy of Tachosil when used for dura mater sealing.

 

As with any protein-containing product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. If these symptoms occur, the administration has to be discontinued immediately.

 

5.1 Pharmacodynamic properties

Text in red added:

 

…..

However, the second study investigating tissue sealing in 299 patients (149 TachoSil, 150 standard surgical treatment) with demonstrated intraoperative air leakage showed the superiority of TachoSil compared to standard treatment.

 

The efficacy of TachoSil was tested in a randomised controlled study in 726 patients (362 treated with TachoSil and 364 controls) undergoing skull base surgery as an adjunct to suture for sealing the dura mater, in which the efficacy outcome was measured post-operatively as verified cerebrospinal fluid (CSF) leaks or pseudomeningocoele, or treatment failure during surgery. In this study, superiority over current practise practice (which included suture, duraplasty and fibrin and polymer sealants or combinations of these) could not be documented. The numbers of subjects experiencing an efficacy outcome event were 25 (6.9%) and 30 (8.2%) for TachoSil and current practice treated patients, respectively, providing an Odds Ratio of 0.82 (95% CI: 0.47, 1.43). However, the 95% confidence intervals for the odds ratio results indicated that TachoSil had similar efficacy to current practice. In this study two application techniques for TachoSil were evaluated: application of TachoSil over the dura and application of TachoSil on both sides of the dura. The results did not support the second method. TachoSil was found to be well tolerated and safe for use as an adjunct to dura mater closure in neurosurgery.

 

6.6 Special precautions for disposal and other handling

Text in red added:

 

 

The active side of TachoSil should be applied so that it extends 1‑2 cm beyond the margins of the wound. If more than one matrix is used they should overlap. TachoSil can be cut to the correct size and shaped if too large.

 

In neurosurgery, TachoSil should be applied on top of the primary dura closure.

 

Pre-rolled TachoSil can be used for both open surgery and in minimally invasive surgery, and it can pass through a 10 mm or larger port or trocar.

 

10. Date of revision of the text

Updated text in red:

 

30th March 2016

Updated on 26 February 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company


Please note that formatting and typographical corrections have occurred throughout SmPC. Only key additions/deletions to text have been provided below.

Change to section

Details of change

4.4 Special warnings and precautions for use

Text in red removed:

 

Do not use intravascularly. Life threatening thromboembolic complications may occur if the preparation is unintentionally applied intravascularly.

 

Text in red added:

 

As with any protein-containing product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. If these symptoms occur, the administration has to be discontinued immediately.

4.8 Undesirable effects

Text in red added/removed:

 

Immunogenicity:

Antibodies against components of fibrin sealant/haemostatic products may occur rarely.

However, in a clinical trial with TachoSil in hepatic surgery, in which patients were investigated for the development of antibodies, 26% of the 96 patients tested and treated with TachoSil developed antibodies to equine collagen. The equine collagen antibodies that developed in some patients after TachoSil use were not reactive with human collagen. One patient developed antibodies to human fibrinogen.

There were no adverse events attributable to the development of human fibrinogen or equine collagen antibodies.

There is very limited clinical data available regarding re-exposure to TachoSil. Two subjects have been re-exposed in a clinical trial and have not reported any immune-mediated adverse events; however, their antibody status to collagen or fibrinogen is unknown.

 

Thromboembolic complications may occur if the preparation is unintentionally applied intravascularly (see section 4.4)

 

Frequency of undesirable effects for TachoSil based on all adverse event data from six clinical trials, two post-authorisation safety studies and spontaneous reporting.

 

Tabulated summary of adverse reactions

Data from the six eight controlled clinical trials conducted by the MAH has been pooled into an integrated dataset. The frequencies of occurrence in this SmPC originate from this integrated dataset. In the integrated analyses, 521 997 patients were treated with TachoSil and 511 984 patients were treated with comparator treatment. Due to practical reasons (comparison to standard surgical and standard haemostatic treatment), blinding was not possible in the TachoSil trials. Therefore the studies were performed as open-label studies.

 

Tabulated summary of adverse reactions

 

The following adverse reactions have been reported with TachoSil during post marketing experience. The frequency of all of the events listed below has been categorised as not known (cannot be estimated from the available data).

The following categories are used to rank the undesirable effects by frequency of occurrence: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); and very rare (<1/10,000), not known (cannot be estimated from the available data).

 

Frequency

 

Organ class

Common

(³1/100 to <1/10)

Uncommon

(³1/1,000 to <1/100)

Very rare

(<1/10,000), not known (cannot be estimated from the available data)

Immune system disorders

 

Hypersensitivity

 

Vascular disorders

 

 

Thromboembolism

(if applied intravascularly)

Gastrointestinal disorders

 

 

Intestinal obstruction (in abdominal surgeries)

General disorders and administration site conditions

Pyrexia

 

Adhesions

*Pyrexia occurred in 6.3% of the patients treated with TachoSil and in 5.9% of the patients treated with comparator treatment.

 

System organ class

Frequency not known

 

Immune system disorders

Anaphylactic shock, Hypersensitivity

Vascular disorders

Thrombosis

Gastrointestinal disorders

Intestinal obstruction (in abdominal surgeries)

General disorders and administration site conditions

Adhesions

 

 

10. Date of revision of the text

Updated:

 

4 February 2016

Updated on 23 February 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 23 February 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration

Updated on 28 January 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Change to section

Details of change

4.4 Special warnings and precautions for use

Added:

 

To prevent the development of tissue adhesions at undesired sites, ensure tissue areas outside the desired application area are adequately cleansed before administration of TachoSil (see section 6.6). Events of adhesions to gastrointestinal tissues leading to gastrointestinal obstruction have been reported with use in abdominal surgery carried out in proximity to the bowel.

 

4.8 Undesirable effects

Text in red added:

 

Frequency

 

Organ class

Common

(³1/100 to <1/10)

Uncommon

(³1/1,000 to <1/100)

Frequency not known

Immune system disorders

 

Hypersensitivity

 

Vascular disorders

 

 

Thromboembolism

(if applied intravascularly)

Gastrointestinal disorders

 

 

Intestinal obstruction (in abdominal surgeries)

General disorders and administration site conditions

Pyrexia*

 

Adhesions

 

 

 

6.6 Special precautions for disposal and other handling

Added text in red:

 

Pressure is applied with moistened gloves or a moist pad. Due to the strong affinity of collagen to blood, TachoSil may also stick to surgical instruments, gloves or adjacent tissues covered with blood. This can be avoided by cleansing surgical instruments, and gloves and adjacent tissues before application. It is important to note that failure to adequately clean adjacent tissues may cause adhesions (see section 4.4). After pressing TachoSil to the wound, the glove or the pad must be removed carefully. To avoid TachoSil from being pulled loose it may be held in place at one end, e.g. with a pair of forceps.

 

 

10. Date of revision of the text

Updated:

 

6 January 2016

Updated on 28 January 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 24 August 2015 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 23 October 2014 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company



CHANGE TO SECTION

DETAILS OF CHANGE

1.         NAME OF THE MEDICINAL PRODUCT

Changed:

 

‘‘TachoSil medicated sponge’’

to

‘’TachoSil sealant matrix’’

 

3.         PHARMACEUTICAL FORM

Changed:

 

‘‘Medicated sponge’’

to

‘’Sealant matrix’’

 

‘’TachoSil is an off-white sponge sealant matrix. The active side of the sponge matrix, which is coated with fibrinogen and thrombin, is marked by a yellow colour’’.

 

4.2      POSOLOGY AND METHOD OF ADMINISTRATION

The quantity number of TachoSil sponges to be applied should always be oriented towards the underlying clinical need for the patient. The quantity number of TachoSil sponges to be applied is governed by the size of the wound area.

 

Application of TachoSil must be individualised by the treating surgeon. In clinical trials, the individual dosages have typically ranged from 1-3 spongeunits (9.5 cm x 4.8 cm); application of up to 7 sponge units has been reported. For smaller wounds, e.g. in minimally invasive surgery the smaller size sponge matrices (4.8 cm x 4.8 cm or 3.0 cm x 2.5 cm) or the pre-rolled matrix (based on a matrix of 4.8 cm x 4.8 cm) is recommended.

 

Method and route of administration

For epilesional use local use only.

 

 

4.4       SPECIAL WARNINGS AND PRECAUTIONS FOR USE

 

For local use epilesional use only.

4.8.   UNDESIRABLE EFFECTS     

    

Added:

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

 

 

6.5     NATURE AND CONTENTS OF CONTAINER

Changed:

 

Each sponge sealant matrix is packed in a PET-GAG blister sealed with a coated PE foil. The blister is packed in an aluminium-bonded foil sachet with a desiccant bag included and packed in a folding carton.

 

Pack sizes:

Package with 1 spongematrix of 9.5 cm x 4.8 cm

Package with 2 spongematrices of 4.8 cm x 4.8 cm

Package with 1 spongematrix of 3.0 cm x 2.5 cm

Package with 5 spongematrices of 3.0 cm x 2.5 cm

 

Added:

Package with 1 pre-rolled matrix of 4.8 cm x 4.8 cm

 

6.6     SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER  HANDLING

Changed:

 

After removal of the conventional, flat TachoSil from the sterile package it the sponge should be pre-moistened in saline solution and then applied immediately. The yellow, active side of the sponge matrix is applied to the bleeding/leaking surface and held against it with a gentle pressure for 3-5 minutes.

 

Added:

After removal of the pre-rolled TachoSil from the sterile package it should be applied immediately through the trocar without pre-moistening. While unrolling the matrix the yellow, active side of the matrix is applied to the bleeding/leaking surface using e.g. a pair of cleansed forceps and held against it with a moist pad under gentle pressure for 3-5 minutes. This procedure enables an easy adhesion of TachoSil to the wound surface.

 

Changed:

This can be avoided by pre-moisteningcleansing surgical instruments and gloves with physiological saline solutionbefore application. After pressing TachoSil to the wound, the glove or the pad must be removed carefully. To avoid the spongeTachoSil from being pulled loose it may be held in place at one end, e.g. with a pair of forceps.

 

Changed:

The active side of TachoSil sponge should be applied so that it extends 1-2 cm beyond the margins of the wound. If more than one spongematrix is used they sponges should overlap. The spongeTachoSil can be cut to the correct size and shaped if too large.

 

Added:

Pre-rolled TachoSil can be used for both open surgery and in minimally invasive surgery, and it can pass through a 10 mm or larger port or trocar.

 

10.      DATE OF REVISION OF THE TEXT

Changed to:

25th September 2014

Updated on 23 October 2014 PIL

Reasons for updating

  • Change to date of revision
  • Introduction of new pack/pack size
  • Change to product name
  • Addition of information on reporting a side effect.

Updated on 27 December 2013 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 8 May 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Section 7: Change of Marketing Authorisation Holder to  Takeda Austria GmbH

Section 10: Date of Revision of the text: 1 March 2013

Updated on 8 May 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 8 January 2013 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

The updated TachoSil SmPC contains additional information in the following section(s):

 

4.3 Contraindications- Additional contraindication added:

TachoSil must not be applied intravascularly.

 

5.2 Pharmacokinetic Properties- Rewording and additional information to include:

 

TachoSil is intended for  epilesional use only. Intravascular administration is contraindicated.

As a consequence, intravascular pharmacokinetic studies were not performed in man.

Fibrin Sealants/haemostatics are metabolized in the same way as endogenous fibrin by fibrinolysis and phagocytosis.

 

In animal studies, TachoSil biodegrades after administration to a wound surface with few remnants left after 13 weeks. Complete degradation of TachoSil was seen in some animals 12 months after its administration to a liver wound, whereas small remnants were still observed in others. The degradation was associated with infiltration of granulocytes and formation of resorptive granulation tissue encapsulating the degraded remnants of TachoSil. No evidence of local intolerability has been observed in animal studies.

 

From the experience in humans there have been isolated cases where remnants were observed as coincidental findings with no signs of functional impairment

 

Updated on 8 January 2013 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 14 October 2011 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 29 July 2010 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 23 July 2010 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Section 6.5

Each sponge is packed in a polystyrene blister sealed with a peel lacquer laminate paper. The blister is packed in an aluminium-bonded foil sachet with a desiccant bag included and packed in a folding carton.

Section 6.5

Each sponge is packed in a PET-GAG blister sealed with a coated PE foil. The blister is packed in an aluminium-bonded foil sachet with a desiccant bag included and packed in a folding carton.

Updated on 26 May 2009 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Section 4.1, Therapeutic Indications, has been updated to include promotion of tissue sealing and suture support in vascular surgery.  Section 4.4, Special Warnings, and Section 5.1, Pharmcodynamic Properties, have also been consequentially updated to remove the respective warnings and to update the clinical data respectively.
 
Section 4.8, Undesirable Effects, has been updated to distinguish between events reported during clinical trials and post-marketing.
 
 

Updated on 21 January 2008 PIL

Reasons for updating

  • Change to MA holder contact details
  • Change to date of revision

Updated on 13 December 2006 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

  • Section 2: 'a full list of' added in last sentence to read 'For a full list of excipients, see section 6.1'
  • Section 4.4: heading amended in line with updated EMEA guidance (on original document)
  • Section 5.1: ATC code updated to B02BC30
  • Section 6.6: heading amended in line with updated EMEA guidance (on original document)
  • Section 10: Date of revision, 08 November 2006

Updated on 23 June 2006 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 21 June 2006 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to restricted prescription (C)